Syndax Pharmaceuticals, Inc. (SNDX) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Syndax Pharmaceuticals, Inc. (SNDX) Bundle
Optimize your time and improve precision with our (SNDX) DCF Calculator! Utilizing actual data from Syndax Pharmaceuticals and customizable assumptions, this tool empowers you to forecast, analyze, and evaluate Syndax like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.5 | 1.5 | 139.7 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 9109.56 | -100 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA | -55.6 | -70.3 | 27.3 | -151.8 | -229.9 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | -3664.86 | -4633.22 | 19.53 | 100 | 100 | 3.91 | 3.91 | 3.91 | 3.91 | 3.91 |
Depreciation | .5 | .5 | .5 | .5 | .0 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 29.73 | 33.95 | 0.32639 | 100 | 100 | 52.8 | 52.8 | 52.8 | 52.8 | 52.8 |
EBIT | -56.0 | -70.8 | 26.8 | -152.2 | -230.0 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | -3694.59 | -4667.17 | 19.2 | 100 | 100 | 3.84 | 3.84 | 3.84 | 3.84 | 3.84 |
Total Cash | 59.8 | 293.1 | 439.9 | 481.3 | 577.6 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .1 | .2 | .4 | 4.1 | 1.2 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 7.65 | 11.54 | 0.30707 | 100 | 100 | 43.9 | 43.9 | 43.9 | 43.9 | 43.9 |
Inventories | 1.7 | 5.3 | 7.7 | -4.3 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 110.55 | 348.25 | 5.48 | 100 | 100 | 81.1 | 81.1 | 81.1 | 81.1 | 81.1 |
Accounts Payable | 6.2 | 3.5 | 5.7 | 4.4 | 10.0 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 407.25 | 231.25 | 4.06 | 100 | 100 | 80.81 | 80.81 | 80.81 | 80.81 | 80.81 |
Capital Expenditure | .0 | .0 | -.1 | -.2 | .0 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 0 | 0 | -0.09233478 | 100 | 100 | -0.01846696 | -0.01846696 | -0.01846696 | -0.01846696 | -0.01846696 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -56.0 | -70.7 | 26.8 | -146.5 | -230.0 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -51.1 | -76.5 | 26.7 | -139.3 | -225.8 | -8.7 | .0 | .0 | .0 | .0 |
WACC, % | 8.79 | 8.79 | 8.79 | 8.78 | 8.79 | 8.79 | 8.79 | 8.79 | 8.79 | 8.79 |
PV UFCF | ||||||||||
SUM PV UFCF | -8.0 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -8 | |||||||||
Net Debt | -294 | |||||||||
Equity Value | 286 | |||||||||
Diluted Shares Outstanding, MM | 70 | |||||||||
Equity Value Per Share | 4.06 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real SNDX financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe how your inputs affect Syndax Pharmaceuticals' valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- 🔍 Real-Life SNDX Financials: Pre-filled historical and projected data for Syndax Pharmaceuticals, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Syndax’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Syndax’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file for Syndax Pharmaceuticals, Inc. (SNDX).
- Step 2: Review Syndax’s pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust assumptions.
- Step 5: Analyze the outputs and leverage the results for your investment decisions.
Why Choose This Calculator for Syndax Pharmaceuticals (SNDX)?
- Accuracy: Utilizes real Syndax financial data to ensure precise calculations.
- Flexibility: Tailored for users to easily test and adjust inputs as needed.
- Time-Saving: Avoid the complexity of constructing a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and usability expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for users without extensive financial modeling skills.
Who Should Use This Product?
- Individual Investors: Gain insights to make informed decisions about buying or selling Syndax Pharmaceuticals (SNDX) stock.
- Financial Analysts: Enhance valuation processes with comprehensive financial models tailored for Syndax Pharmaceuticals (SNDX).
- Consultants: Provide clients with expert valuation analysis of Syndax Pharmaceuticals (SNDX) swiftly and accurately.
- Business Owners: Learn how biotech companies like Syndax Pharmaceuticals (SNDX) are valued to inform your own business strategy.
- Finance Students: Explore valuation methodologies using real-world data and case studies related to Syndax Pharmaceuticals (SNDX).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Syndax Pharmaceuticals historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), featuring parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models illustrating intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Syndax Pharmaceuticals.
- Dashboard and Charts: Visual summary of valuation outputs and assumptions for easy result analysis.